Symbol | Exchange | Currency |
|---|
Tetra Technologies (TTI): Q2 Non-GAAP EPS of -$0.02 misses by $0.03; GAAP EPS of -$0.05.Revenue of $102.33M (+6.5% Y/Y) misses by $4.62M.Adjusted EBITDA was up 44% from the first...
Trillium Therapeutics (TRIL) has dosed the first acute myeloid leukemia ((AML)) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate...
Trillium Therapeutics (TRIL) announces that it has dosed the first patient with TTI-621 (SIRPα-IgG1 Fc), an investigational checkpoint inhibitor of the innate immune system,...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,702.50 | 2,713.00 | 2,689.70 | -10.1 | -0.37% | 983.80K | NASDAQ | |||
| 358.92 | 360.48 | 351.51 | +7.68 | +2.19% | 14.18M | NASDAQ | |||
| 146.94 | 148.67 | 134.92 | +8.15 | +5.87% | 1.55M | NASDAQ | |||
| 538.88 | 541.30 | 535.41 | +1.89 | +0.35% | 854.60K | NYSE | |||
| 29.84 | 35.24 | 29.81 | -3.75 | -11.16% | 85.50M | NYSE | |||
| 244.36 | 245.47 | 229.85 | +14.18 | +6.16% | 3.68M | NASDAQ | |||
| 202.74 | 203.18 | 198.28 | +4.59 | +2.32% | 23.13M | NASDAQ | |||
| 45.19 | 45.80 | 45.01 | -0.49 | -1.07% | 43.39M | NYSE | |||
| 70.39 | 85.00 | 54.40 | +23.59 | +50.41% | 175.79M | NASDAQ | |||
| 35.04 | 37.78 | 34.97 | -2.74 | -7.25% | 962.36K | NASDAQ | |||
| 262.12 | 266.66 | 261.68 | -4.70 | -1.76% | 712.83K | NYSE | |||
| 45.09 | 45.80 | 44.56 | +0.52 | +1.17% | 35.45M | NYSE | |||
| 53.90 | 54.44 | 53.70 | -0.16 | -0.30% | 17.61M | NASDAQ | |||
| 200.71 | 203.27 | 196.91 | +3.33 | +1.69% | 22.33M | NYSE | |||
| 81.98 | 83.09 | 79.54 | +1.12 | +1.39% | 29.18M | NASDAQ |
TETRA Technologies, Inc., together with its subsidiaries, operates as a diversified oil and gas services company. It operates through two segments, Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products segment manufactures and markets clear brine fluids, additives, and associated products and services to the oil and gas industry for use in well drilling, completion, and workover operations in the United States, as well as in Latin America, Europe, Asia, the Middle East, and Africa. This segment also markets liquid and dry calcium chloride products. The Water & Flowback Services segment provides water management services for onshore oil and gas operators. This segment also offers frac flowback, production well testing, offshore rig cooling, and other associated services in oil and gas producing regions in the United States and Mexico, as well as in various basins in Latin America, Africa, Europe, and the Middle East. The company was incorporated in 1981 and is headquartered in The Woodlands, Texas.